1. Home
  2. LOPE vs CRSP Comparison

LOPE vs CRSP Comparison

Compare LOPE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LOPE

Grand Canyon Education Inc.

HOLD

Current Price

$168.59

Market Cap

4.5B

Sector

Real Estate

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.82

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOPE
CRSP
Founded
1949
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.9B
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
LOPE
CRSP
Price
$168.59
$56.82
Analyst Decision
Buy
Buy
Analyst Count
2
17
Target Price
$220.00
$70.29
AVG Volume (30 Days)
203.3K
1.4M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.71
N/A
Revenue
$511,257,000.00
$289,590,000.00
Revenue This Year
$8.67
$743.50
Revenue Next Year
$6.66
$163.21
P/E Ratio
$21.48
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$149.37
$33.03
52 Week High
$223.04
$78.48

Technical Indicators

Market Signals
Indicator
LOPE
CRSP
Relative Strength Index (RSI) 51.71 65.66
Support Level $162.24 $51.64
Resistance Level $173.28 $60.63
Average True Range (ATR) 4.66 2.28
MACD -0.36 1.17
Stochastic Oscillator 36.30 94.14

Price Performance

Historical Comparison
LOPE
CRSP

About LOPE Grand Canyon Education Inc.

Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: